secwatch.observer — SEC 8-K summary
======================================

Issuer:     Parabilis Medicines, Inc. (PBLS)
CIK:        0001657677
Form:       8-K
Filed at:   2026-08-13T11:19:04+00:00
Accession:  0001193125-26-347869
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Parabilis Q2 net loss $52.5M; $1.1B cash after $770.5M IPO; Regeneron deal up to $2.2B
--------------------------------------------------------------------------------

- Net loss $52.5M in Q2 2026 vs $34.8M prior year; R&D $39.4M, G&A $11.7M.
- Cash $1.1B as of June 30, 2026 (vs $27.7M Dec 31, 2025) after $770.5M IPO at $20.00/share; funds ops into 2030.
- Regeneron collaboration: $125M received ($50M upfront + $75M equity); up to $2.2B milestones plus low double-digit tiered royalties for Antibody-Helicon Conjugates.
- Zolucatetide: ESMO 2026 abstract accepted; FDA alignment Q4 2026; Phase 3 desmoid trial initiation H1 2027; FAP cohort H2 2026.
- Leadership: Helen Ho (Chief Business & Strategy Officer), Tom Kotarakos (CFO), Alan M. Sebulsky to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1657677/000119312526347869/0001193125-26-347869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1657677/000119312526347869/ck0001657677-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-347869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer